Cargando…
PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731195/ https://www.ncbi.nlm.nih.gov/pubmed/33266349 http://dx.doi.org/10.3390/ijms21239147 |
_version_ | 1783621850336591872 |
---|---|
author | Lassalle, Sandra Nahon-Esteve, Sacha Frouin, Eric Boulagnon-Rombi, Camille Josselin, Nicolas Cassoux, Nathalie Barnhill, Raymond Scheller, Boris Baillif, Stéphanie Hofman, Paul |
author_facet | Lassalle, Sandra Nahon-Esteve, Sacha Frouin, Eric Boulagnon-Rombi, Camille Josselin, Nicolas Cassoux, Nathalie Barnhill, Raymond Scheller, Boris Baillif, Stéphanie Hofman, Paul |
author_sort | Lassalle, Sandra |
collection | PubMed |
description | Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8, PD-1 in CM and investigated whether there was an association between the expression of these markers and the BRAF and NRAS molecular profile as well as some clinico-pathological criteria. A total of sixty-five CM were assessed for PD-L1, PD-1, and CD8 expression by immunohistochemistry (IHC) and for BRAF and NRAS genomic alterations using molecular biology techniques and anti-BRAF and anti-NRAS antibodies. PD-L1 expression in tumour cells (TC) was very low or absent but detected in tumour-infiltrating immune cells (IC). A correlation was observed between the expression of PD-L1, CD8, and PD-1 in IC. No correlation between PD-L1 expression (in tumour and/or immune cells) and BRAF or NRAS mutations was observed. PD-L1 expression in IC correlated with a higher pTNM stage and PD-L1 expression in TC with worse disease-specific survival. PD-L1 expression is a potential prognostic biomarker that correlates with poor prognosis in CM patients. |
format | Online Article Text |
id | pubmed-7731195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77311952020-12-12 PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome Lassalle, Sandra Nahon-Esteve, Sacha Frouin, Eric Boulagnon-Rombi, Camille Josselin, Nicolas Cassoux, Nathalie Barnhill, Raymond Scheller, Boris Baillif, Stéphanie Hofman, Paul Int J Mol Sci Article Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8, PD-1 in CM and investigated whether there was an association between the expression of these markers and the BRAF and NRAS molecular profile as well as some clinico-pathological criteria. A total of sixty-five CM were assessed for PD-L1, PD-1, and CD8 expression by immunohistochemistry (IHC) and for BRAF and NRAS genomic alterations using molecular biology techniques and anti-BRAF and anti-NRAS antibodies. PD-L1 expression in tumour cells (TC) was very low or absent but detected in tumour-infiltrating immune cells (IC). A correlation was observed between the expression of PD-L1, CD8, and PD-1 in IC. No correlation between PD-L1 expression (in tumour and/or immune cells) and BRAF or NRAS mutations was observed. PD-L1 expression in IC correlated with a higher pTNM stage and PD-L1 expression in TC with worse disease-specific survival. PD-L1 expression is a potential prognostic biomarker that correlates with poor prognosis in CM patients. MDPI 2020-11-30 /pmc/articles/PMC7731195/ /pubmed/33266349 http://dx.doi.org/10.3390/ijms21239147 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lassalle, Sandra Nahon-Esteve, Sacha Frouin, Eric Boulagnon-Rombi, Camille Josselin, Nicolas Cassoux, Nathalie Barnhill, Raymond Scheller, Boris Baillif, Stéphanie Hofman, Paul PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome |
title | PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome |
title_full | PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome |
title_fullStr | PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome |
title_full_unstemmed | PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome |
title_short | PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome |
title_sort | pd-l1 expression in 65 conjunctival melanomas and its association with clinical outcome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731195/ https://www.ncbi.nlm.nih.gov/pubmed/33266349 http://dx.doi.org/10.3390/ijms21239147 |
work_keys_str_mv | AT lassallesandra pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT nahonestevesacha pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT frouineric pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT boulagnonrombicamille pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT josselinnicolas pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT cassouxnathalie pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT barnhillraymond pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT schellerboris pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT baillifstephanie pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome AT hofmanpaul pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome |